Finanzen von Matinas BioPharma Holdings Inc (MTNB)MTNBMatinas BioPharma Holdings Inc

Evaluating the bottom line, Matinas BioPharma Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -154.28%, provide a clear picture of how effectively MTNB converts its operational activities into shareholder value.

In the context of the broader market, MTNB competes directly with industry leaders such as PRFX and GNPX. With a market capitalization of $3.44M, it holds a significant position in the sector. When comparing efficiency, MTNB's gross margin of N/A stands against PRFX's -4776.47% and GNPX's N/A. Such benchmarking helps identify whether Matinas BioPharma Holdings Inc is trading at a premium or discount relative to its financial performance.

Matinas has reported consistent losses over the past several quarters, with a net income of -$4.27 million in Q3 2024 and a current ratio that has dropped to 0.85 in Q2 2026, indicating potential liquidity issues. The company's total equity has also significantly decreased, from $15.78 million in Q3 2024 to $1.8 million in Q2 2026.